PUBLISHER: Acute Market Reports | PRODUCT CODE: 1166105
PUBLISHER: Acute Market Reports | PRODUCT CODE: 1166105
Chagas disease or American trypanosomiasis, is inflammatory disease caused by protozoan parasite Trypanosoma cruzi. It is characterized by inflammation of tissue, mostly of the heart and intestinal tract. According to the World Health Organization (WHO), about 8 million people are infected with chagas disease around the globe, predominantly in Latin America. WHO and the Center for disease control and prevention (CDC) considered chagas disease as a neglected tropical disease. Rising number of traveling and migrating individuals from Latin America to other countries is the prime factor driving the growth of chagas disease drugs market in non-endemic countries. Increase in urbanization in Latin America and population migration from endemic regions have led to the chagas disease being increasingly diagnosed in non-endemic regions. Among the European countries, Spain has larger number of chagas disease affected population due to the highest number of immigrants incoming from Latin America.
The report titled "Chagas Disease Drugs Market - Growth, Future Prospects and Competitive Analysis, 2022-2030" covered in-depth information related to chagas disease drugs market accompanied by market size estimated for duration 2020 to 2030. The research study provides detail information related to market segment including drug type and geography. Based on the drug class, the global chagas disease drugs market is categorized into Benznidazole, Nifurtimox and others. There is no vaccine available in market for treatment of chagas disease; but, anti-parasitic drugs Benznidazole, Nifurtimox are used effectively in treatment of chagas disease.
For the purpose of the study, the global chagas disease drugs market is regionally categorized as North America (United States and Canada), Latin America (Argentina, Brazil, Mexico and Rest of Latin America), and Europe (Spain, France, United Kingdom and rest of Europe) because affected population exist in these regions mostly.
Quantitative and qualitative information are included in report for in-depth analysis of current market scenario and future prospects. For better understanding of ongoing trends of market, factors such as drivers, opportunities and challenges about the market are also included in the report.
Currently, there is no vaccine available for the treatment of chagas disease; however, a few parasitic drugs are used in treatment. Benznidazole and Nifurtimox have shown efficacy in treatment of chagas disease. These drugs can completely cure the disease if administered at earlier stage. Benznidazole and Nifurtimox are included in the World Health Organization's (WHO) list of essential medicine for children. In the recent years, Benznidazole is the major revenue generating segment, as the drugs is used as first line treatment option due to its safety and efficacy. Benznidazole is the first approved drug in the United States for the treatment of chagas disease. Previously, Benznidazole was available in the United States through a special program run by the CDC. In August 2021, the FDA approved Benznidazole by using the accelerated approval pathway and granted orphan drug designation. However, problems in drug supply, drug shortages, limited accessibility and lack of guidelines supporting implementation are hindering the growth of chagas disease drugs market. Nifurtimox is not yet approved by FDA in United States, but it can be accessed via the CDC under expanded access protocol. Other drugs such as angiotensin-converting enzyme inhibitors, angiotensin receptor blockers and adrenergic beta-blockers etc. are used to reduce mortality. Pacemakers, ablations, implantable cardioverter-defibrillators or heart transplantation etc. are used in patients with later stage of the chagas disease.
Chagas disease is one of the biggest public health issues in Latin America, causing more than 10,000 deaths each year. The highest number of chagas disease population exists in Argentina, Brazil, and Mexico, followed by Bolivia and Colombia. The WHO and the Center for disease control and prevention (CDC) considered chagas disease as a neglected tropical disease. Benznidazole and Nifurtimox are recommended for treatment of chagas disease. It is estimated that, the United States will show the fastest market growth during forecast period primarily due to higher healthcare awareness among the general population and increase in number of migrated population from endemic regions to the United States. Chagas disease largely affects people in rural parts of Latin America but due to growing number of population migrating from endemic countries to the United States, number of affected population increased in United States. According to the CDC, there about 300,000 persons infected with Chagas disease in the United States. Previously, Benznidazole was available via the CDC in the United States; however, due to increase in number of affected population, FDA granted approval to Benznidazole (in August 2021). Benznidazole is the first and the only approved drug in the United States for chagas disease treatment.
Historical & Forecast Period
This study report represents analysis of each segment from 2020 to 2030 considering 2021 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2022 to 2030.
The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.
Research Methodology
The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation of Americas And Europe Chagas Disease Drugs market are as follows:
Research and development budgets of manufacturers and government spending
Revenues of key companies in the market segment
Number of end users and consumption volume, price and value.
Geographical revenues generate by countries considered in the report
Micro and macro environment factors that are currently influencing the Americas And Europe Chagas Disease Drugs market and their expected impact during the forecast period.
Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.
Market Segmentation
Drug
Benznidazole
Nifurtimox
Others
Region Segment (2020-2030; US$ Million)
North America
U.S.
Canada
Rest of North America
UK and European Union
UK
Germany
Spain
Italy
France
Rest of Europe
Asia Pacific
China
Japan
India
Australia
South Korea
Rest of Asia Pacific
Latin America
Brazil
Mexico
Rest of Latin America
Middle East and Africa
GCC
Africa
Rest of Middle East and Africa
Global Impact of Covid-19 Segment (2020-2021; US$ Million )
Pre Covid-19 situation
Post Covid-19 situation
Key questions answered in this report
What are the key micro and macro environmental factors that are impacting the growth of Americas And Europe Chagas Disease Drugs market?
What are the key investment pockets with respect to product segments and geographies currently and during the forecast period?
Estimated forecast and market projections up to 2030.
Which segment accounts for the fastest CAGR during the forecast period?
Which market segment holds a larger market share and why?
Are low and middle-income economies investing in the Americas And Europe Chagas Disease Drugs market?
Which is the largest regional market for Americas And Europe Chagas Disease Drugs market?
What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?
Which are the key trends driving Americas And Europe Chagas Disease Drugs market growth?
Who are the key competitors and what are their key strategies to enhance their market presence in the Americas And Europe Chagas Disease Drugs market worldwide?